DK1327143T3 - Krystalstruktur af BACE og anvendelse deraf - Google Patents

Krystalstruktur af BACE og anvendelse deraf

Info

Publication number
DK1327143T3
DK1327143T3 DK01973243T DK01973243T DK1327143T3 DK 1327143 T3 DK1327143 T3 DK 1327143T3 DK 01973243 T DK01973243 T DK 01973243T DK 01973243 T DK01973243 T DK 01973243T DK 1327143 T3 DK1327143 T3 DK 1327143T3
Authority
DK
Denmark
Prior art keywords
bace
crystal structure
agents
alzheimer
beta
Prior art date
Application number
DK01973243T
Other languages
English (en)
Inventor
Rajiv Choppa
Kristine Svenson
Bethany Annis
Tatos N Akopian
Jonathan Bard
Mark Lloyd Stahl
William S Somers
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of DK1327143T3 publication Critical patent/DK1327143T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
DK01973243T 2000-09-22 2001-09-19 Krystalstruktur af BACE og anvendelse deraf DK1327143T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23457600P 2000-09-22 2000-09-22
PCT/US2001/029387 WO2002025276A1 (en) 2000-09-22 2001-09-19 Crystal structure of bace and uses thereof

Publications (1)

Publication Number Publication Date
DK1327143T3 true DK1327143T3 (da) 2007-07-02

Family

ID=22881945

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01973243T DK1327143T3 (da) 2000-09-22 2001-09-19 Krystalstruktur af BACE og anvendelse deraf

Country Status (8)

Country Link
US (1) US7630838B2 (da)
EP (1) EP1327143B1 (da)
AT (1) ATE355520T1 (da)
AU (1) AU2001292843A1 (da)
DE (1) DE60126970T2 (da)
DK (1) DK1327143T3 (da)
ES (1) ES2282292T3 (da)
WO (1) WO2002025276A1 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2374346C (en) 1999-06-28 2010-06-22 Jordan J. N. Tang Inhibitors of memapsin 2 and use thereof
US7601528B1 (en) * 2000-12-23 2009-10-13 Elan Pharmaceuticals, Inc. Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in alzheimer's disease
US7217556B1 (en) 2000-12-23 2007-05-15 Pfizer Inc Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in Alzheimer's disease
US7806980B2 (en) 2000-12-23 2010-10-05 Elan Pharmaceuticals, Inc. Method for crystallizing human beta secretase in complex with an inhibitor
US20040121947A1 (en) * 2000-12-28 2004-06-24 Oklahoma Medical Research Foundation Compounds which inhibit beta-secretase activity and methods of use thereof
US7524668B1 (en) 2001-05-10 2009-04-28 Elan Pharmaceuticals, Inc. Crystal of human beta secretase having monoclinic space group symmetry C2 and methods for crystallization thereof
US7384773B1 (en) * 2001-05-10 2008-06-10 Pfizer Inc Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof
CA2464736A1 (en) 2001-10-23 2003-05-15 Oklahoma Medical Research Foundation Beta-secretase inhibitors and methods of use
US20060234944A1 (en) * 2001-10-23 2006-10-19 Oklahoma Medical Reseach Foundation Beta-secretase inhibitors and methods of use
CH698246B1 (de) * 2001-12-20 2009-06-30 Hoffmann La Roche Test zur Identifizierung von Inhibitoren von Beta-Sekretasen.
US20040014194A1 (en) * 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
US7442537B1 (en) 2002-05-10 2008-10-28 Elan Pharmaceuticals, Inc. Crystals of unliganded beta secretase and/or beta secretase-like proteins and the use thereof
US7166454B1 (en) * 2002-05-24 2007-01-23 Schering Corporation Codon-optimized β-secretase and methods of refolding and processing
WO2004011641A2 (en) * 2002-07-26 2004-02-05 Astex Technology Limited Crystal structure of beta-site app-cleaving enzyme (bace) mutants and uses thereof
AU2003285892A1 (en) * 2002-10-15 2004-05-04 Bristol-Myers Squibb Company Bace binding peptides and uses thereof
MXPA05004033A (es) 2002-10-16 2005-06-08 Isis Innovation Hidroxilasas de asparaginil y moduladores de las mismas.
AU2006208226A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
BRPI0608581A2 (pt) * 2005-03-14 2010-01-19 Transtech Pharma Inc derivados de benzazol, composiÇÕes e mÉtodos de uso como inibidores de b-secretase
CA2618508A1 (en) * 2005-08-10 2007-02-22 Oklahoma Medical Research Foundation Truncated memapsin 2 for use for treating alzheimer's disease
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
EP2261254A3 (en) 2007-12-21 2011-04-13 Amgen, Inc Anti-amyloid antibodies and uses thereof
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
EP2281824A1 (en) 2009-08-07 2011-02-09 Noscira, S.A. Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
CN103228674B (zh) 2010-11-10 2019-07-05 霍夫曼-拉罗奇有限公司 用于神经疾病免疫疗法的方法和组合物
JP2013542973A (ja) 2010-11-22 2013-11-28 ノスシラ、ソシエダッド、アノニマ 神経変性疾患または神経変性状態を治療するためのビピリジンスルホンアミド誘導体
US20180107782A1 (en) * 2014-01-20 2018-04-19 Stevan Hubbard Atomic model for janus kinase-2 (jak2) and uses thereof
EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
CN107108745B (zh) 2014-11-19 2021-01-12 基因泰克公司 抗bace1的抗体和其用于神经疾病免疫疗法的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5331573A (en) * 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
US5942400A (en) * 1995-06-07 1999-08-24 Elan Pharmaceuticals, Inc. Assays for detecting β-secretase
GB9626022D0 (en) * 1996-12-14 1997-01-29 Smithkline Beecham Plc Novel compounds
EP0848062A3 (en) * 1996-12-14 2000-07-05 Smithkline Beecham Corporation Aspartic protease ASP1
GB9701684D0 (en) * 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
US6313268B1 (en) * 1998-10-16 2001-11-06 Vivian Y. H. Hook Secretases related to Alzheimer's dementia
CA2374346C (en) * 1999-06-28 2010-06-22 Jordan J. N. Tang Inhibitors of memapsin 2 and use thereof
US20040137518A1 (en) * 2002-01-31 2004-07-15 Lambert Millard Hurst CRYSTALLIZED PPARa LIGAND BINDING DOMAIN POLYPEPTIDE AND SCREENING METHODS EMPLOYING SAME

Also Published As

Publication number Publication date
US7630838B2 (en) 2009-12-08
US20020055459A1 (en) 2002-05-09
ATE355520T1 (de) 2006-03-15
WO2002025276A1 (en) 2002-03-28
EP1327143B1 (en) 2007-02-28
DE60126970D1 (de) 2007-04-12
DE60126970T2 (de) 2007-11-22
EP1327143A1 (en) 2003-07-16
EP1327143A4 (en) 2005-02-09
AU2001292843A1 (en) 2002-04-02
ES2282292T3 (es) 2007-10-16

Similar Documents

Publication Publication Date Title
DK1327143T3 (da) Krystalstruktur af BACE og anvendelse deraf
ATE350044T1 (de) Thrombopoietinmimetika
EE05507B1 (et) Rosuvastatiini ZD4522) kasutamine heterosgootseperekondliku hperkolesteroleemia raviks
DE60025632D1 (de) Thrombopoietin-mimetika
PT1169370E (pt) Solucoes de poliuretano contendo unidades estruturais de alcoxissilano.
DE60025812D1 (de) Jak-3 hemmer zur behandlung von allergischen störungen
MY136707A (en) Thrombopoietin mimetics
CO5611160A2 (es) Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos
ATE245032T1 (de) Verwendung von neurotoxinen in medikamenten zur behandlung von thyroidstörungen
BR0107691A (pt) Sapogeninas substituìdas e seu uso
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
HUP0104709A2 (hu) Eritropoietin vagy eritropoietrinszármazékok alkalmazása agyi iszkémiák kezelésére használható gyógyszer előállítására
TR200502508T2 (tr) IL-18 İnhibitörlerinin kullanımı.
NO20031860L (no) Kahalalid F
BR9807523A (pt) Quinoxalinas em combinação tripla com inibidores da protease e inibidores de transcriptase reversa como medicamentos para o tratamento de aids.
EE04055B1 (et) Ühendid ja kompositsioonid seriinproteaasse, eriti trüptaasse aktiivsusega seotud haiguste raviks, ja nende kasutamine
DE50103006D1 (de) Mikrobizid wirksame tenside
TR199802704T2 (xx) H�V tedavisinde Vx478, Zidov�din, FTC ve/veya 3TC i�eren kombinasyonlar�n kullan�m�.
DE60101559D1 (de) Benutzung von comt-inhibitoren als analgetika
TR200402030T4 (tr) İkame edilen I-aminobutan-3-ol-türevleri
DE60110087D1 (de) Verwendung von Carboanhydrase-Inhibitoren zur Prävention von diabetischer Retinopathie bei Diabetikern
TR200002939T2 (tr) Paroksetin maleat
EA200400751A1 (ru) Применение дезоксипеганина для лечения клинической депрессии
BR9914722A (pt) Derivados de anticonvulsivo úteis no tratamento de dependência, vìcio e abuso do álcool
DE60009315D1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung